Last reviewed · How we verify
SK10
At a glance
| Generic name | SK10 |
|---|---|
| Sponsor | Guangzhou Zhiyi Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Inactivated Bacteroides Fragilis for Prevention of Chemotherapy-Induced Diarrhea (NA)
- A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SK10 CI brief — competitive landscape report
- SK10 updates RSS · CI watch RSS
- Guangzhou Zhiyi Biotechnology Co., Ltd. portfolio CI